Choosing Appropriate Estimands in Clinical Trials

被引:0
作者
Ann-Kristin Leuchs
Jörg Zinserling
Andreas Brandt
Dorothee Wirtz
Norbert Benda
机构
[1] Federal Institute for Drugs and Medical Devices (BfArM),
来源
Therapeutic Innovation & Regulatory Science | 2015年 / 49卷
关键词
clinical trials; estimands; efficacy; effectiveness; nonadherence; missing data;
D O I
暂无
中图分类号
学科分类号
摘要
Lack of adherence to study protocol and missing data are often unavoidable in clinical trials, and both increase the need to differentiate between the ideal treatment effect if the medication is taken as directed and the treatment effect in presence of the actual adherence pattern. In this regard, estimands have become the focus of attention. An estimand is simply that which is being estimated. In the context of treatment benefit, an estimand may address either efficacy or effectiveness aspects. Defining the estimand of interest is an essential step to take before deciding on trial design and primary analysis. The choice of estimand has consequences for various other factors to be considered during any clinical trial’s planning phase. This study presents a process chart including all aspects to consider during planning. After deciding on the primary estimand, the trial design should be specified, followed by the primary analysis. Both should appropriately address the chosen estimand. Finally, sensitivity analyses should be taken into account. Provided are suggestions for all the planning steps involved, especially on choosing between efficacy and effectiveness, and relevant examples from clinical practice to illustrate them. It is recommended that one bear in mind the process chart during planning of any clinical trial and give reasonable justification for each decision in the study protocol.
引用
收藏
页码:584 / 592
页数:8
相关论文
共 65 条
  • [11] Roger JH(2003)Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations J Biopharm Stat 13 179-190
  • [12] Kenward MG(2004)The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA Clin Trials 1 477-489
  • [13] Mallinckrodt CH(2003)Assessing and interpreting treatment effects in longitudinal clinical trials with missing data Biol Psychiatry 53 754-760
  • [14] Lin Q(2004)Analyzing incomplete longitudinal clinical trial data Biostatistics 5 445-464
  • [15] Lipkovich I(2007)Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials Drug Inf J 42 303-319
  • [16] Molenberghs G(2014)A multiple-imputation-based approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials J Biopharm Stat 24 211-228
  • [17] Fleming TR(2013)Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models Pharm Stat 12 337-347
  • [18] Gibbons RD(1996)Intention-to-treat analysis for longitudinal studies with drop-outs Biometrics 52 1324-1333
  • [19] Hedeker D(2014)Estimation of the treatment effect in the presence of non-compliance and missing data Stat Med 33 193-208
  • [20] Elkin I(2010)Aspects of modernizing drug development using clinical scenario planning and evaluation Drug Inf J 44 297-315